U.S. Diabetic Neuropathy Market, by Drug (Tricyclic Antidepressants (Amitriptyline, Nortyptyline, Imipramine, Desipramine), SSRI (Paroxetine, Citalopram), Anticonvulsants (Gabapentin, Pregabalin, Carbamazepine), Opioids (Tramadol, Tapentadol, Oksikodon),

U.S. Diabetic Neuropathy Market, by Drug (Tricyclic Antidepressants (Amitriptyline, Nortyptyline, Imipramine, Desipramine), SSRI (Paroxetine, Citalopram), Anticonvulsants (Gabapentin, Pregabalin, Carbamazepine), Opioids (Tramadol, Tapentadol, Oksikodon), SNRIs (Duloxetine), Other Drugs (Capsaicin, Lidocaine, Botilinum Toxin)) by Type (Peripheral Neuropathy, Proximal Neuropathy, Autonomic Neuropathy, Focal Neuropathy), by Route of Administration (Oral, Topical, Injection (Intramuscular)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Diabetic neuropathy is a serious and common complication of type 1 and type 2 diabetes. Diabetic neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower leg, it develops slowly, sometimes over the course of decades. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. Peripheral neuropathy is the most common form of neuropathy. Over time, high blood glucose levels, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage your nerves. High blood glucose levels can also damage the small blood vessels that nourishes the nerves with oxygen and nutrients. There is no cure for diabetic neuropathy but the nerve pain can be managed with medication and exercise.

Market Dynamics

Increasing adoption of inorganic strategies such as collaborative agreement by key market players is expected to drive the U.S. diabetic neuropathy market over the forecast period. For instance, in June 2020, NeuroMetrix, Inc., a medical device company, announced that they had signed a collaborative agreement with BioMedix, a manufacturer of diagnostic and surgical equipment, to comarket DPNCheck for peripheral neuropathy detection within medicare advantage. This agreement will provide complementary diagnostic tests to physicians and health plans by combining results from multiple diagnostic tests into one data exchange file for the electronic medical record system.

Key features of the study:

• This report provides an in-depth analysis of the U.S. diabetic neuropathy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. diabetic neuropathy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., GSK plc., Glenmark Pharmaceuticals Ltd., Lupin, Regenacy Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited, Abbott, Ionis Pharmaceuticals, NeuroMetrix, Inc., Tissue Tech, Inc., and Averitas Pharma, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. diabetic neuropathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. diabetic neuropathy market

Detailed Segmentation:

• U.S. Diabetic Neuropathy Market, By Drug:
• Tricyclic Antidepressants

Amitriptyline

Nortyptyline

Imipramine

Desipramine

• SSRI

Paroxetine

Citalopram

• Anticonvulsants

Gabapentin

Pregabalin

Carbamazepine

Others (Oxcarbazepine, Topiramate and Others)

• Opioids

Tramadol

Tapentadol

Oksikodon

• SNRIs

Duloxetine

• Other Drugs

Capsaicin

Lidocaine

Botilinum Toxin

• U.S. Diabetic Neuropathy Market, By Type:
• Peripheral Neuropathy
• Proximal Neuropathy
• Autonomic Neuropathy
• Focal Neuropathy
• U.S. Diabetic Neuropathy Market, By Route of Administration:
• Oral
• Topical
• Injection (Intramuscular)
• U.S. Diabetic Neuropathy Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Company Profiles
• Eli Lilly and Company*

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer, Inc.
• GSK plc.
• Glenmark Pharmaceuticals Ltd.
• Lupin
• Regenacy Pharmaceuticals, Inc.
• Alembic Pharmaceuticals Limited
• Abbott
• Ionis Pharmaceuticals
• NeuroMetrix, Inc.
• Tissue Tech, Inc.
• Averitas Pharma, Inc.

“*” marked represents similar segmentation in other categories in the respective section.